Novo Nordisk news

On 29 January 2009, Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

A global survey studying children with diabetes has identified a failure of current healthcare systems to give adequate social and psychological support for young people with diabetes. The current lack of support often leads to poor control of their disease resulting in long-term health complications.

Novo Nordisk today announced a major investment in a new insulin production plant in Tianjin, China. The plant has been designated Novo Nordisk’s primary production base in the Asia Pacific region and will supply both China and export markets.

Novo Nordisk A/S, a world leader in diabetes care, Cellartis AB, a forefront stem cell biotechnology company, and Lund University Stem Cell Center today signed a collaborative research agreement for the development of insulin-producing cells from human stem cells.

MONTREAL – Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD™ 6) comparing the investigational new drug liraglutide to exenatide.

Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. In addition, Novo Nordisk receives fully paid-up exclusive rights to NN8555/IPH 2301.

Data from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published today by The Lancet.

Novo Nordisk today announced that it has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose’s proprietary GlycoPEGylation technology. The acquired rights are currently subject to a license from Neose for Novo Nordisk’s development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX.

Rome, Italy – Data released today at the European Association for the Study of Diabetes (EASD) Annual Meeting concludes that Levemir® (insulin detemir [rDNA origin] injection) is a once-daily treatment for diabetes patients after demonstrating a 24-hour duration of action in both type 1 and type 2 diabetes.1,2 Results from two other studies announced today reveal that Levemir® can lead to signific

Novo Nordisk announced today that it has reached a settlement with the Danish Public Prosecutor for Serious Economic Crime regarding the company’s sales to Iraq during 2000 to 2003 under the United Nations Oil-for-Food programme. Under the terms of the settlement, Novo Nordisk will pay back past profits of 30 million Danish kroner.